Compare ASMB & SXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | SXC |
|---|---|---|
| Founded | 2005 | 1960 |
| Country | United States | United States |
| Employees | N/A | 848 |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 516.5M |
| IPO Year | 2010 | 2011 |
| Metric | ASMB | SXC |
|---|---|---|
| Price | $28.24 | $6.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $43.40 | $9.00 |
| AVG Volume (30 Days) | 92.6K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | ★ 7.95% |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,600,300,000.00 |
| Revenue This Year | $33.33 | N/A |
| Revenue Next Year | N/A | $4.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.30 |
| 52 Week Low | $7.76 | $5.52 |
| 52 Week High | $39.71 | $9.82 |
| Indicator | ASMB | SXC |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 40.50 |
| Support Level | $26.50 | $5.52 |
| Resistance Level | $30.66 | $6.49 |
| Average True Range (ATR) | 1.46 | 0.29 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 36.74 | 60.40 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.